Citius Oncology, Inc. announced the initial shipment of LYMPHIR™ to Europe through a regional distribution partner, expanding international access via Named Patient Programs following its U.S. launch.
Key takeaways
Initial shipment of LYMPHIR™ to Europe via regional partner marks first international order fulfillment.
LYMPHIR™ available in Europe through Named Patient Programs per local regulations.
U.S. commercial launch ongoing since December 2025 with progress in formulary access and payer coverage.
LYMPHIR™ FDA-approved in August 2024 for relapsed/refractory Stage I-III CTCL after prior systemic therapy.
Company is majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR).